National Institute of Rheumatology and Physiotherapy, Budapest, Hungary.
Autoimmun Rev. 2010 Feb;9(4):195-9. doi: 10.1016/j.autrev.2009.07.004. Epub 2009 Jul 27.
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging from mild to severe types. In patients with SLE, the incidence and risk of malignancy development is increased, and mostly non-Hodgkin's lymphoma (NHL), cervical cancer, as well as bronchial carcinomas occur. Besides others, the common genetic predisposition, chronic antigen stimulus, disproportional immune responses, as well as the chronic administration of immunosuppressive medications can contribute to the development of malignancies in lupus. In this review we present the molecular pathology, as well as the epidemiological and clinical aspects of malignancies in patients with SLE.
系统性红斑狼疮（SLE）是一种典型的系统性自身免疫性疾病，其特征为广泛的症状和器官受累，导致不同的疾病过程和结局，从轻到重不等。在 SLE 患者中，恶性肿瘤的发病率和风险增加，主要是非霍奇金淋巴瘤（NHL）、宫颈癌以及支气管癌。除其他因素外，常见的遗传易感性、慢性抗原刺激、不成比例的免疫反应以及慢性免疫抑制药物治疗也可能导致狼疮患者发生恶性肿瘤。在这篇综述中，我们介绍了 SLE 患者恶性肿瘤的分子病理学以及流行病学和临床方面。
